Please login to the form below

What impact do GPs think the new NHS cancer guide will have?

What impact do GPs think the new NHS cancer guide will have? Doctors are being told to extend cancer tests to half a million more patients a year under new NHS guidelines. With pharma companies investing heavily in understanding how to optimise service design, e.g. by supporting the development of integrated care pathways; we were keen to understand what impact the guidelines would have. Will earlier diagnosis allow increased access to optimal treatment approaches in many oncology indications?
Doctors are being told to extend cancer tests to half a million more patients a year under the new NHS guidelines. It’s claimed that the move could prevent 5,000 deaths a year by speeding up diagnosis and ensuring more patients have a full range of treatment options available to them.

The guide – designed to be used by doctors and patients – signposts for the very first time the symptoms that could be indicative of one of 37 cancers. GPs can already request X-rays, blood tests and some scans, but under the new guidelines will be able to get fast-tracked endoscopy investigations and MRI or CT brain scan tests, historically ordered by a specialist following referral.


The guidelines suggest great promise for increased diagnosis rates and the number of patients eligible for treatment at diagnosis.


But what do GPs think about the new guidance?
With pharma companies investing heavily in understanding how to optimise service design, e.g. by supporting the development of integrated care pathways; Adelphi was keen to understand what impact the guidelines would have.


Claire Nelson, one of Adelphi’s NHS Leads said “service redesign to optimise diagnosis and management is critical in today’s NHS. Ensuring patients are treated at the right time, in the right place and with the right treatment is key. Pharma companies are increasingly looking to support the NHS to optimise both efficiency and patient service in this way e.g. by supporting early diagnosis to ensure curative treatments are an option for as many patients as possible”.

Adelphi wanted to better understand to what extent the new guidelines might underpin these efforts. We set out to investigate the extent to which GPs think they will be following the guide, what impact GPs think the guide is likely to have on patient outcomes, how easy they will be to implement and whether the GP service will need to change to accommodate the guide.

Key findings
Although over half of the GPs surveyed were unsure of the extent to which the guidelines would be implemented in their practice, there was a strong consensus that they would lead to an improvement in patient outcomes.

Most felt the changes recommended by the guidelines would be easy to implement with only 12% feeling that substantial change to GP services would be required to accommodate the new protocols.


Rebecca Marshall-Clarke, Adelphi’s Oncology lead says “If adhered to these guidelines offer hope to patients whose early cancer symptoms are easy to miss. The guidelines empower GPs to fully investigate patients presenting with symptoms that could be linked to conditions such as myeloma, lung cancer and ovarian cancer, without the need for secondary care referral. These conditions often first present with symptoms such as cough or back pain, that are easily attributable to other benign causes. Pharma companies now have the opportunity to support the NHS by raising awareness of early indicators in these types of indications, so that GPs can diagnose early or rule them out’.

For more information contact aruk@adelphigroup.com or visit www.adelphiresearchuk.co.uk

14th July 2015

Share

Tags

Company Details

Adelphi Research UK

01625 572828

Contact Website

Address:
Adelphi Mill
Bollington
Macclesfield
Cheshire
SK10 5JB
United Kingdom

Latest content on this profile

How Can We Make Payer Communications Really Sing?
With so many different influences at play in access decisions, how can we make sure we tap into what’s really driving payer decision-making. How do we go beyond the stated drivers to understand the inherent biases at play?
Adelphi Research UK
Team Updates from Adelphi

Adelphi Research UK
Adelphi Research UK Welcomes Six New Starters
Having recently announced several promotions, Adelphi Research UK is growing, with the appointment of six new starters.
Adelphi Research UK
Adelphi Research UK Announces Several Promotions
Adelphi Research UK is having a great start to the year with several promotions recently announced.
Adelphi Research UK
Adelphi Research UK Overview
Adelphi Research UK is a healthcare insight partner that uniquely blends robust primary market research with a consultancy approach. Experts in a range of tried and tested as well as innovative digital and co-creative methods, we have extensive access to HCPs, Payers, Patients and Policy Makers. What gets us out of bed in the morning? ...the drive to deliver robust insights that truly Inspire Action.
Adelphi Research UK
Getting personal with wearable tech
From the brightly coloured Fitbits, to the plethora of health apps available for Apple’s iWatch, it’s easy to see how the global market for wearable technology is on the increase, and how it’s fast becoming the new craze
Adelphi Research UK